A
Here are the TLDR points from the episode:
Peptide hormones are short amino acid chains (3–50 residues) cut from larger precursor proteins and released in response to stimuli, not continuously active like enzymes.
One gene can produce different peptides depending on tissue-specific processing (e.g., preproglucagon → glucagon in pancreas, GLP-1 in gut).
Peptides signal via GPCRs, acting over minutes but can trigger longer-term gene expression changes before being rapidly broken down.
Endogenous GLP-1 is a gut hormone released after meals that boosts insulin, but it has a very short half-life and limited brain penetration.
Natural GLP-1 mainly affects peripheral glucose control rather than strong appetite suppression in the brain.
Drug versions of GLP-1 (e.g., weight-loss medications) are engineered for stability and brain access via:
DPP-4 resistance
Lipid modification → albumin binding → longer circulation
At higher doses, GLP-1 drugs reach brain regions (hypothalamus, hindbrain) and reduce appetite and change food preference.
Low doses primarily affect blood sugar via pancreatic insulin secretion; higher doses drive weight loss effects via central nervous system action.
Researchers are using genomic/computational methods to scan for unknown peptide precursors across the genome.
Hundreds of previously uncharacterized peptides may exist with distinct biological roles.
A newly discovered peptide (“BRP”) reduces feeding in mice even without GLP-1 receptors.
BRP activates different neural circuits than GLP-1 and does not slow gastric emptying, suggesting a separate pathway for appetite control.
Overall theme: metabolism and appetite are regulated by a much larger and still partially unknown “peptide signaling system,” beyond GLP-1 alone.
No comments:
Post a Comment